4-Fluoromethamphetamine

From Wikipedia, the free encyclopedia
4-Fluoromethamphetamine
Systematic (IUPAC) name
(RS)-1-(4-fluorophenyl)-N-methylpropan-2-amine
Clinical data
Legal status ?
Identifiers
CAS number 351-03-1 N
52063-62-4 (hydrochloride)
ATC code ?
PubChem CID 11745017
ChemSpider 9919721 YesY
Chemical data
Formula C10H14FN 
Mol. mass 167.223
 N (what is this?)  (verify)

4-Fluoromethamphetamine (4-FMA) is a stimulant drug related to methamphetamine and 4-fluoroamphetamine. It has been reported to be sold on the illicit market as a controlled substance analogue, but little is known about its pharmacology or toxicology as yet.[1] It was first detected from legal highs sold in Japan in 2006 and became illegal to sell or to possess for the purpose of distribution (it's significant that not illegal to possess for personal use only) in Japan in 2008.[2] It was initially reported to be contained as an ingredient in some of the range of party pills sold internationally by the Israeli company Neorganics from around 2006 onwards, but this was later shown to be incorrect and this ingredient was eventually identified as the closely related compound 2-fluoromethamphetamine.[3]

Pharmacology

4-FMA is a CYP450 inhibitor. It reduces the metabolism of methamphetamine, which has the effect of increasing its potency, duration and systemic toxicity while also reducing its cellular toxicity.[4][5]

See also

References

  1. Rösner, P.; Quednow, B.; Girreser, U.; Junge, T. (2005). "Isomeric Fluoro-methoxy-phenylalkylamines: A new series of controlled-substance analogues (designer drugs)". Forensic Science International 148 (2–3): 143–156. doi:10.1016/j.forsciint.2004.05.003. PMID 15639609. 
  2. Machiko Nagashima, Takako Seto, Misako Takahashi, Jin Suzuki, and Ichirou Yasuda (2006). "Spectrum Data of the 3rd Governor-designated Drugs and the Analyses of Uncontrolled Drugs Purchased". Ann. Rep. Tokyo Metr. Inst.P.H. 57: 109–113. 
  3. Camilleri, A; Johnston, MR; Brennan, M; Davis, S; Caldicott, DG (2010). "Chemical analysis of four capsules containing the controlled substance analogues 4-methylmethcathinone, 2-fluoromethamphetamine, alpha-phthalimidopropiophenone and N-ethylcathinone". Forensic Science International 197 (1–3): 59–66. doi:10.1016/j.forsciint.2009.12.048. PMID 20074881. 
  4. Cherner, M.; Bousman, C.; Everall, I. A. N.; Barron, D.; Letendre, S.; Vaida, F.; Atkinson, J. H.; Heaton, R.; Grant, I.; Hnrc, G. (2010). "Cytochrome P450-2D6 extensive metabolizers are more vulnerable to methamphetamine-associated neurocognitive impairment: Preliminary findings". Journal of the International Neuropsychological Society 16 (5): 890–901. doi:10.1017/S1355617710000779. PMC 3543816. PMID 20727252. 
  5. Taniguchi, Masashi; Yamamoto, Yoshio; Nishi, Katsuji (2013). "Comparative in Vitro Studies of the Metabolism of Six 4-Substituted Methamphetamines and Their Inhibition of Cytochrome P450 2D6 by GC-MS with Trifluoroacetyl Derivatization". American Journal of Analytical Chemistry 04 (4): 166. doi:10.4236/ajac.2013.44022. 


This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.